TET2 and essential thrombocythemia: All 75 ET patients received antiplatelet or cytoreductive therapy, and the incidence of thrombosis after follow-up treatment was significantly higher in ET patients with TET2 mutations than in those without TET2 mutations (p = 0.032) (Table 5).